Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer effect on protein-bound uremic toxins in non-dialysis CKD with hyperphosphatemia
TCTR20181018003Phase 3Recruiting
- Start
- Oct 2018
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of sevelamer carbonate in chronic kidney disease (CKD), hyperphosphatemia, sponsored by None. Started Oct 2018; status: recruiting.
02
Drugs
sevelamer carbonate
03
Conditions
chronic kidney disease (CKD)hyperphosphatemia
Beyond the preview
Go deeper on TCTR20181018003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20181018003.